ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma.
Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, Federkiel Y, Huang H, Hoefflin R, Adlesic M, Witt C, Hoffmann DJ, Metzger P, Lindemann RK, Zenke FT, Schell C, Boerries M, von Elverfeldt D, Reichardt W, Follo M, Albers J, Frew IJ.
Seidel P, et al. Among authors: huang h.
JCI Insight. 2022 Dec 22;7(24):e156087. doi: 10.1172/jci.insight.156087.
JCI Insight. 2022.
PMID: 36413415
Free PMC article.